Narcolepsy Trial, Recruiting NCT06457945 Sponsor: Hospices Civils de Lyon Condition: Narcolepsy
Back to Narcolepsy

Narcolepsy Trial, Recruiting

NCT06457945
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Narcolepsy Type 1 (NT1) or Idiopathic Hypersomnia (IH) based on recognised international sleep disorder guidelines
  • If you have Idiopathic Hypersomnia, you have had a specific sleep test (MSLT) that showed you fall asleep unusually quickly (confirm with trial site for exact test results required)
  • You experience excessive daytime sleepiness with no identifiable cause, and have already had a thorough series of tests (including sleep studies, brain scans, and a psychiatric consultation) that ruled out other reasons for your sleepiness

Who may not be able to join:

  • You have cognitive (thinking or memory) difficulties that would prevent you from completing the tasks involved in the trial
  • You are currently taking antidepressant medication
  • Your excessive sleepiness is caused by another identified condition, such as untreated severe sleep apnea, a body-clock sleep disorder, not getting enough sleep, a physical or mental health condition, or the use of sedating substances
  • You have an unstable medical or psychiatric condition at the time of the trial
  • You do not wish to take part

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Laure PETER-DEREX, Professor, Hospices Civils de Lyon

Phone: +33 04 72 07 19 29

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
3 December 2024
Est. completion
3 December 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Difference in accuracy in responses between high-and low- probability trials during the ASRT; Difference in reaction time in responses between high-and low- probability trials during the ASRT

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov